NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

PFS is relevant because NWBO and FDA agreed that it was the PRIMARY ENDPOINT for the P3 trial. DCVax-L failed the primary endpoint and NWBO tossed it out and redid the whole trial protocol after the trial was virtually completed.